Evaxion Biotech A/S EVAX.OQ EVAX.O is expected to show a rise in quarterly revenue when it reports results on October 31 for the period ending September 30 2024
The Copenhagen Denmark-based company is expected to report revenue of $123.33 thousand, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Evaxion Biotech A/S is for a loss of 31 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Evaxion Biotech A/S is $8.00, above its last closing price of $2.84.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -0.36 | -0.39 | -0.12 | Beat | 69.2 |
Mar. 31 0001 | -0.50 | -0.55 | 0.30 | Beat | 154.1 |
Dec. 31 2023 | -1.60 | -1.60 | -1.60 | Met | 0 |
Sep. 30 2023 | -1.95 | -2.10 | Missed | -7.7 | |
Jun. 30 2023 | -2.15 | -2.15 | -2.10 | Beat | 2.3 |
Mar. 31 2023 | -2.43 | -2.40 | -2.40 | Met | 0 |
Dec. 31 2022 | -2.63 | -2.90 | Missed | -10.1 | |
Sep. 30 2022 | -2.64 | -2.67 | -2.40 | Beat | 10 |
This summary was machine generated October 29 at 13:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。